The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target<7.0%

被引：0

作者：

Liebl, A.

Prager, R.

Kaiser, M.

Binz, K.

Gailwitz, B.

机构：

[1] Ctr Diabet & Metabol, Dept Diabet, Bad Heilbrunn, Germany

[2] L Boltzmann Res Inst Metab Dis & Nutr, Dept Diabet, Vienna, Austria

[3] Novo Nordisk Pharm GmbH, Mainz, Germany

[4] Triemli City Hosp, Dept Diabet, Zurich, Switzerland

[5] Univ Tubingen, Dept Diabet, Tubingen, Germany

来源：

DIABETOLOGIA | 2006年 / 49卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0998

引用

页码：610 / 611

页数：2

共 50 条

[31] Similar glucose control with basal bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification
Malek, R.
Ajili, F.
Assaad-Khalil, S. H.
Shinde, A.
Chen, J. W.
Van den Berg, E.
DIABETES & METABOLISM, 2015, 41 (03) : 223 - 230
[32] Use of a New Basal Insulin with a Bolus Boost (IDegAsp) in Type 2 Diabetes: Comparison with Biphasic Insulin Aspart 30 (BIAsp 30)
Vaag, Allan
Leiter, Lawrence A.
Franek, Edward
Weng, Jianping
Damci, Taner
Munoz Torres, Manuel
Donnet, Jean-Paul
Endahl, Lars
Skjoth, Trine V.
Niskanen, Leo
DIABETES, 2011, 60 : A313 - A313
[33] IDegAsp lowers the rate of hypoglycaemia vs biphasic insulin aspart 30 in adults with type 2 diabetes achieving glycaemic target (HbA1c <7.0%): a meta-analysis
Vaag, A.
Christiansen, J. S.
Niskanen, L.
Johansen, T.
Rasmussen, S.
Fulcher, G.
DIABETOLOGIA, 2014, 57 : S400 - S400
[34] Insulin Degludec/Insulin Aspart (IDegAsp) Twice Daily (BID) vs. Biphasic Insulin Aspart 30 (BIAsp 30) BID-A Randomized Trial in Chinese Patients with Type 2 Diabetes
Yang, Wenying
Ma, Jianhua
Hong, Tianpei
Liu, Ming
Miao, Heng
Peng, Yongde
Wang, Changjiang
Xu, Xiangjin
Yang, Tao
Nielsen, Anne Moeller
Pan, Lili
Liu, Weihong
Zhao Weigang
DIABETES, 2018, 67
[35] Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - A pilot study
Shanmugasundar, G.
Bhansali, Anil
Walia, Rama
Dutta, Pinaki
Upreti, Vimal
INDIAN JOURNAL OF MEDICAL RESEARCH, 2012, 135 (01) : 78 - 83
[36] A comparison of the cost-effectiveness of basal-bolus therapy of Type 1 diabetes using insulin detemir plus insulin aspart versus human insulin-based regimens
Palmer, AJ
Roze, S
Valentine, WJ
Smith, IC
Wittrup-Jensen, K
DIABETOLOGIA, 2004, 47 : A344 - A344
[37] Comparison of Thrice Daily Biphasic Human Insulin Versus Basal Detemir and Bolus Aspart in Patients with Poorly Controlled Type 2 Diabetes Mellitus.
Bhansali, Anil
Sanmugasundar, G.
Dutta, Pinaki
Sachdeva, Naresh
ENDOCRINE REVIEWS, 2010, 31 (03)
[38] Efficacy and Safety of Fast-Acting Insulin Aspart According to Baseline HbA1c in Adults with Type 2 Diabetes Treated with a Basal-Bolus Regimen
Franek, Edward
Ekelund, Magnus
Thorisdottir, Olof
Jang, Hak Chul
Lalic, Katarina
Rathor, Naveen
Rose, Ludger
Gonzalez, Alfonso Soto
Silver, Robert J.
Lane, Wendy
DIABETES, 2020, 69
[39] A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal-Bolus Therapy in Insulin-Naive Patients with Type 2 Diabetes
Linjawi, Sultan
Lee, Byung-Wan
Tabak, A-mur
Lovdahl, Susanna
Werther, Shanti
Abusnana, Salahedeen
DIABETES THERAPY, 2018, 9 (01) : 1 - 11
[40] Switching from a human insulin basal-bolus regimen to insulin analog basal-bolus therapy with insulin detemir/insulin aspart improves glycemic control and reduces hypoglycemic episodes in patients with type 1 diabetes:: Results from German subgroup of the PREDICTIVE™ study
Maxeiner, Stephan
Hansen, Jes B.
Nauck, Michael
DIABETES, 2006, 55 : A127 - A127

← 1 2 3 4 5 →

The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target&lt;7.0%

The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target<7.0%